Apellis Average Receivables from 2010 to 2025
| APLS Stock | USD 23.79 0.03 0.13% |
Average Receivables | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check Apellis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Apellis Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 42.4 M or Selling General Administrative of 526.1 M, as well as many indicators such as Price To Sales Ratio of 5.29, Dividend Yield of 0.0 or PTB Ratio of 18.84. Apellis financial statements analysis is a perfect complement when working with Apellis Pharmaceuticals Valuation or Volatility modules.
Apellis | Average Receivables |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.